<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF77BFB6-C66E-441F-AFE3-94353782E01C"><gtr:id>EF77BFB6-C66E-441F-AFE3-94353782E01C</gtr:id><gtr:name>University of Tokyo</gtr:name><gtr:address><gtr:line1>University of Tokyo</gtr:line1><gtr:line2>Bunkyo-Ku</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/621CACAB-53EE-48C8-A5EF-69DA4FA58943"><gtr:id>621CACAB-53EE-48C8-A5EF-69DA4FA58943</gtr:id><gtr:name>Leibniz Association</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC"><gtr:id>AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC</gtr:id><gtr:name>Johannes Gutenberg University of Mainz</gtr:name><gtr:address><gtr:line1>University of Mainz</gtr:line1><gtr:line4>Mainz</gtr:line4><gtr:postCode>D-55099</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF77BFB6-C66E-441F-AFE3-94353782E01C"><gtr:id>EF77BFB6-C66E-441F-AFE3-94353782E01C</gtr:id><gtr:name>University of Tokyo</gtr:name><gtr:address><gtr:line1>University of Tokyo</gtr:line1><gtr:line2>Bunkyo-Ku</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/621CACAB-53EE-48C8-A5EF-69DA4FA58943"><gtr:id>621CACAB-53EE-48C8-A5EF-69DA4FA58943</gtr:id><gtr:name>Leibniz Association</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC"><gtr:id>AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC</gtr:id><gtr:name>Johannes Gutenberg University of Mainz</gtr:name><gtr:address><gtr:line1>University of Mainz</gtr:line1><gtr:line4>Mainz</gtr:line4><gtr:postCode>D-55099</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FDF8C76C-8825-40D1-BBD6-BFBDF5E5555C"><gtr:id>FDF8C76C-8825-40D1-BBD6-BFBDF5E5555C</gtr:id><gtr:firstName>Steve</gtr:firstName><gtr:surname>Anderton</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G117%2F515"><gtr:id>E1DAC258-94D7-4C35-A381-F6C02E958D2B</gtr:id><gtr:title>Studies on autoimmune T cell tolerance and memory</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G117/515</gtr:grantReference><gtr:abstractText>Autoimmune diseases develop from an unwanted attack on our own tissues by the cells of the immune system. Multiple sclerosis (MS), for example, results from an autoimmune attack upon the brain and central nervous system. T lymphocytes, white blood cells that direct this attack, recognize defined proteins within the brain. We can take fragments of these proteins and administer them to the autoimmune T lymphocytes to switch off their activity in the laboratory. This holds great promise as a future treatment for MS and other autoimmune diseases. However, when patients reach the clinic the disease is well established after a silent process lasting many months before the first symptoms are noticed. At this stage the autoimmune T cell population is very different from the original naive cells that started the disease - the cells have memory and can be activated far more easily. We do not know if our potential therapy can control these cells (so far it has only been tested on na&amp;iuml;ve cells). In the work proposed here, our team will develop ways to silence the autoimmune memory cells that we must control if we are to treat patients in the clinic.</gtr:abstractText><gtr:technicalSummary>Autoimmune disease results from a failure of the complex control measures used by the immune system to prevent autoaggressive responses to self-antigens. Experimental models have provided important insights into the generation and activation of the autoimmune T cell repertoire, allowing us to develop effective antigen-specific therapies. Provision of peptides containing T cell epitopes can produce profound tolerance in autoimmune CD4+ T cells and has great potential for the treatment of autoimmune disease. In the clinical setting, however, the need is to treat ongoing disease and therefore we must control memory T cell populations. 
The aims of this study are to explore the relationship between tolerance and memory in the context of autoimmunity:- Specifically, a)how is tolerance induced? b) does tolerance allow memory cells to develop? c) can memory cells be tolerized? 
By extending our recent studies on immune tolerance we will examine how exposure to physiological autoantigen influences the sensitivity of autoimmune T cells, and relate this to their subsequent susceptibility to peptide-induced tolerance. This will involve collaboration with a group at the University of Utrecht, The Netherlands in the development of novel reagents to identify heterogeneous autoreactive T cell populations. We will also work with a group at the German Rheumatology Research Centre, Berlin to assess the whether tolerance is mediated by depletion of T cells using particular T cell receptor gene sequences. 
We shall characterize the T cells that persist after tolerance induction with peptide. Specifically, we will test whether these cells differentiate into central memory T cells. These cells are believed to be expanded after sub-optimal antigenic stimulation and represent a potential source of pathogenic T cells after tolerance induction. Clearly, if such cells do arise, we must incorporate strategies that remove them if clinical therapeutic approaches are to succeed.
It is not yet clear whether peptide-induced tolerance can silence autoreactive T cells since these cells have less stringent activation requirements than na&amp;iuml;ve T cells. It is possible that an approach that silences na&amp;iuml;ve T cells could fully activate memory T cells and lead to exacerbation rather than cure in the clinic. By testing these possibilities rigorously, this study is the next crucial step in taking our knowledge of the autoreactive T cell repertoire to the clinic</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>999593</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Cellular and Molecular Medicine</gtr:department><gtr:description>Immune tolerance and autoimmune disease - T cells</gtr:description><gtr:id>76F72BDE-B77A-4DB1-B617-834251EFFC97</gtr:id><gtr:impact>Publications:-
PMID: 18768826</gtr:impact><gtr:outcomeId>ZzKNV2Msqmr-1</gtr:outcomeId><gtr:partnerContribution>Exchange of data and ideas relating to immune tolerance and the nature of pathogenic T cells in CNS autoimmune disease</gtr:partnerContribution><gtr:piContribution>Exchange of data and ideas relating to immune tolerance and the nature of pathogenic T cells in CNS autoimmune disease</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Cellular and Molecular Medicine</gtr:department><gtr:description>T cell function in EAE</gtr:description><gtr:id>41C40CDF-80A8-440A-BC0F-922C90D2DFC0</gtr:id><gtr:impact>PMID 18768826</gtr:impact><gtr:outcomeId>D656F9C2D51-1</gtr:outcomeId><gtr:partnerContribution>Improved understanding of T cell function in EAE</gtr:partnerContribution><gtr:piContribution>T cell differentiation / pathology studies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:description>Immune tolerance in allergic airways disease</gtr:description><gtr:id>1AB19A83-B921-474B-9097-ACCEC48D842A</gtr:id><gtr:impact>Award of MRC CTF - ongoing</gtr:impact><gtr:outcomeId>9DBDD148B0C-1</gtr:outcomeId><gtr:partnerContribution>Expertise in allergic airways disease</gtr:partnerContribution><gtr:piContribution>Expertise in peptide-induced immune tolerance</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leibniz Association</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>German Rheumatism Research Centre (DRFZ)</gtr:department><gtr:description>B cells in autoimmune disease</gtr:description><gtr:id>E89F2896-01E0-4720-A0DF-0A9B3D0734D7</gtr:id><gtr:impact>PMID 16506290, 18354200, 18772002, 18437156, 19037227</gtr:impact><gtr:outcomeId>CDF3D6BDEDB-1</gtr:outcomeId><gtr:partnerContribution>Multiple interactions on T cell and B cell biology</gtr:partnerContribution><gtr:piContribution>Expertise in EAE and T cell biology/tolerance</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leibniz Association</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>German Rheumatism Research Centre (DRFZ)</gtr:department><gtr:description>Immune tolerance and autoimmune disease - B cells</gtr:description><gtr:id>3B8C2984-846E-4E10-8DD7-082467F585E2</gtr:id><gtr:impact>PMID: 18772002 
PMID: 18437156
PMID: 18354200
PMID: 20477161
PMID: 16506290</gtr:impact><gtr:outcomeId>rWpVNYQXNWg-1</gtr:outcomeId><gtr:partnerContribution>Exchange of data and ideas relating to B cell function in CNS autoimmune disease</gtr:partnerContribution><gtr:piContribution>Exchange of data and ideas related to B cell function in autoimmune disease</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Immunology and Infection Research</gtr:department><gtr:description>DC function</gtr:description><gtr:id>7087ACE3-084A-49F4-A42E-8208856AAB27</gtr:id><gtr:impact>PMID 19234175</gtr:impact><gtr:outcomeId>E397B5F7FD3-1</gtr:outcomeId><gtr:partnerContribution>Improved understanding of DC biology in EAE</gtr:partnerContribution><gtr:piContribution>Expertise in T cell differentiation / EAE</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Tokyo</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>Antibodies for T cell tolerance</gtr:description><gtr:id>A6EF41C6-F7FD-4DE8-A00D-E11ED818D248</gtr:id><gtr:impact>Manuscript in press</gtr:impact><gtr:outcomeId>81900F73447-1</gtr:outcomeId><gtr:partnerContribution>Provision of antibodies for immune tolerance studies</gtr:partnerContribution><gtr:piContribution>Expertise in peptide-induced immune tolerance</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johannes Gutenberg University of Mainz</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>T cells and B cells in immune tolerance</gtr:description><gtr:id>4E8BD302-DD95-46C8-B4B9-94D4703937B3</gtr:id><gtr:impact>PMID 18832734 and manuscript in press</gtr:impact><gtr:outcomeId>9F8E74865BF-1</gtr:outcomeId><gtr:partnerContribution>Enhanced understanding of immune tolerance</gtr:partnerContribution><gtr:piContribution>Provision of anti CD25 antibody, expertise in EAE and peptide-induced immune toleance</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Immunology and Infection Research</gtr:department><gtr:description>Antigen presenting cells</gtr:description><gtr:id>9F08EC27-1093-48E7-BC96-AD037E269C5B</gtr:id><gtr:impact>PMID: 20819926 
PMID: 19234175</gtr:impact><gtr:outcomeId>bj3cuFBdW8s-1</gtr:outcomeId><gtr:partnerContribution>Exchange of data, reagents and ideas relating to antigen presenting cell function</gtr:partnerContribution><gtr:piContribution>Exchange of data, reagents and ideas relating to antigen presenting cell function</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johannes Gutenberg University of Mainz</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>CNS autoimmune disease</gtr:description><gtr:id>DACEF09F-3B92-49F2-A70E-6557E0194BC4</gtr:id><gtr:impact>PMID: 18832734
PMID: 20113370</gtr:impact><gtr:outcomeId>PKrR8tE96z8-1</gtr:outcomeId><gtr:partnerContribution>Exchange of data and ideas relating to mechanisms of immune tolerance</gtr:partnerContribution><gtr:piContribution>Exchenge of data and ideas relating to mechanisms of immune tolerance</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>419000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust veterinary post-doctoral fellowship (R. Mellanby)</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>63920ADC-E9B1-4CDC-9E2B-E09AF5322C9D</gtr:id><gtr:outcomeId>51960AD60000</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1900000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0801924</gtr:fundingRef><gtr:id>F476A3C0-B2E8-47B5-923F-FA23833ED728</gtr:id><gtr:outcomeId>7B5A64D5CF80</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Method to test for and avoid anaphylaxis in response to peptide drugs</gtr:description><gtr:id>CC6D55AE-5CBD-49F1-93BF-EA2B7640A14D</gtr:id><gtr:impact>Protocol to use peptides without developing anaphylaxis PMID 18000952</gtr:impact><gtr:outcomeId>E552E4F4FE2</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Tolerance without anaphylaxis</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://europepmc.org/abstract/MED/18000952</gtr:url><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9F1CACEB-7571-4612-9EF9-0517BDA8DE6A</gtr:id><gtr:title>Persistence of autoreactive myelin oligodendrocyte glycoprotein (MOG)-specific T cell repertoires in MOG-expressing mice.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1066c4f22164e465c78066223216072"><gtr:id>c1066c4f22164e465c78066223216072</gtr:id><gtr:otherNames>Fazilleau N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>3EBF3BA4BDE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADCCFE10-B01E-4FAA-ABDA-2C981FD0388D</gtr:id><gtr:title>Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba3ff6ebd6b6261e1b34760ccb07c464"><gtr:id>ba3ff6ebd6b6261e1b34760ccb07c464</gtr:id><gtr:otherNames>Leech MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>E44F96C6072</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57BB2364-CE4C-436A-ABE4-93F1375578DA</gtr:id><gtr:title>CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebdbfe56efad0c6e2fd309804a984d98"><gtr:id>ebdbfe56efad0c6e2fd309804a984d98</gtr:id><gtr:otherNames>Stephens LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>FBB78FB8228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88D70976-A60D-4A89-AD6E-20400A648D63</gtr:id><gtr:title>Circumventing tolerance at the T cell or the antigen-presenting cell surface: antibodies that ligate CD40 and OX40 have different effects.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0973b68765ae853fe11b690a23dc085"><gtr:id>b0973b68765ae853fe11b690a23dc085</gtr:id><gtr:otherNames>Hochweller K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>B1EEA520C61</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EC26321-72A3-4AB2-8046-8FE5581F3E96</gtr:id><gtr:title>Immune regulation by B cells and antibodies a view towards the clinic.</gtr:title><gtr:parentPublicationTitle>Advances in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70e822702587b3b74bf719bf85b2775e"><gtr:id>70e822702587b3b74bf719bf85b2775e</gtr:id><gtr:otherNames>Hoehlig K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0065-2776</gtr:issn><gtr:outcomeId>01A9BF42786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F3CCD96-3005-4051-9D80-2950B440527A</gtr:id><gtr:title>Antigen-based therapies targeting the expansion of regulatory T cells in autoimmune and allergic disease.</gtr:title><gtr:parentPublicationTitle>Chemical immunology and allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba3ff6ebd6b6261e1b34760ccb07c464"><gtr:id>ba3ff6ebd6b6261e1b34760ccb07c464</gtr:id><gtr:otherNames>Leech MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0079-6034</gtr:issn><gtr:outcomeId>FFA16D30FA4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73227D13-D689-4C80-B10C-FA20FC2FF17D</gtr:id><gtr:title>TLR-activated B cells suppress T cell-mediated autoimmunity.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd3a0646322fc1460814e83ec383a64b"><gtr:id>dd3a0646322fc1460814e83ec383a64b</gtr:id><gtr:otherNames>Lampropoulou V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>99A8E1A2547</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F744C35-4322-491F-B268-E2FC3545784E</gtr:id><gtr:title>Distinct T cell recognition of naturally processed and cryptic epitopes within the immunodominant 35-55 region of myelin oligodendrocyte glycoprotein.</gtr:title><gtr:parentPublicationTitle>Journal of neuroimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d11e7536b990ccbc541c0f692dfd166"><gtr:id>4d11e7536b990ccbc541c0f692dfd166</gtr:id><gtr:otherNames>Sweenie CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0165-5728</gtr:issn><gtr:outcomeId>C7044AF72E4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EB46E89-3062-4480-A1E2-337136306EF9</gtr:id><gtr:title>Avoiding autoimmune disease--T cells know their limits.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/376cc62daff5e5b9084b1bce4541554c"><gtr:id>376cc62daff5e5b9084b1bce4541554c</gtr:id><gtr:otherNames>Anderton SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn><gtr:outcomeId>35E6F732A89</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8454C4D-0AF0-4036-A2A6-BC2D8FF47521</gtr:id><gtr:title>Antigen-based therapy and immune-regulation in experimental autoimmune encephalomyelitis.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3029d4e0ab52a045385506e72a6c4d28"><gtr:id>3029d4e0ab52a045385506e72a6c4d28</gtr:id><gtr:otherNames>McGeachy MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>2DB17775F6C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10404752-16E2-4E44-A794-4E4343543EFF</gtr:id><gtr:title>Not always the bad guys: B cells as regulators of autoimmune pathology.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/548b328677c4a0b840ff7ec7e24e679e"><gtr:id>548b328677c4a0b840ff7ec7e24e679e</gtr:id><gtr:otherNames>Fillatreau S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>51E47E00BE2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>107E98FB-4FB9-4C02-BEEE-806C464EF800</gtr:id><gtr:title>Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87b677d4d98cbb244cc46a69c9bbb7d6"><gtr:id>87b677d4d98cbb244cc46a69c9bbb7d6</gtr:id><gtr:otherNames>O'Connor RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>9E48B5A9566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B99C02F-3FD0-459E-9566-DCF9D7F28B04</gtr:id><gtr:title>Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/376cc62daff5e5b9084b1bce4541554c"><gtr:id>376cc62daff5e5b9084b1bce4541554c</gtr:id><gtr:otherNames>Anderton SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>3C7F91CB9B4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9CC3937-B04F-4238-8EE5-C9A7F640E353</gtr:id><gtr:title>IL-10 permits transient activation of dendritic cells to tolerize T cells and protect from central nervous system autoimmune disease.</gtr:title><gtr:parentPublicationTitle>International immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3cc54abeeaeaa1e3ab5b35264e98e86f"><gtr:id>3cc54abeeaeaa1e3ab5b35264e98e86f</gtr:id><gtr:otherNames>Perona-Wright G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0953-8178</gtr:issn><gtr:outcomeId>FB125D3A663</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E78F74F8-2393-434F-A3E1-AFEE76D0C1FC</gtr:id><gtr:title>Tolerance without clonal expansion: self-antigen-expressing B cells program self-reactive T cells for future deletion.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39b330d02d6bdfb8091e5d7ec2f8d1df"><gtr:id>39b330d02d6bdfb8091e5d7ec2f8d1df</gtr:id><gtr:otherNames>Frommer F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>7A55DB5EBE4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6025491-A828-421A-88F0-2B959284E8C8</gtr:id><gtr:title>Activated B cells in autoimmune diseases: the case for a regulatory role.</gtr:title><gtr:parentPublicationTitle>Nature clinical practice. Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/376cc62daff5e5b9084b1bce4541554c"><gtr:id>376cc62daff5e5b9084b1bce4541554c</gtr:id><gtr:otherNames>Anderton SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1745-8382</gtr:issn><gtr:outcomeId>D218D0578B1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D03332AC-961C-4D2B-A6EA-434C99EB0C3A</gtr:id><gtr:title>Death, adaptation and regulation: the three pillars of immune tolerance restrict the risk of autoimmune disease caused by molecular mimicry.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff70155bd50e81c1af2db3363f59bdce"><gtr:id>ff70155bd50e81c1af2db3363f59bdce</gtr:id><gtr:otherNames>Ryan KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>8C19186986E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EF6C894-151E-4A4E-82A1-57CA2CB5CF5E</gtr:id><gtr:title>Immunological tolerance using synthetic peptides--basic mechanisms and clinical application.</gtr:title><gtr:parentPublicationTitle>Current molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0973b68765ae853fe11b690a23dc085"><gtr:id>b0973b68765ae853fe11b690a23dc085</gtr:id><gtr:otherNames>Hochweller K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1566-5240</gtr:issn><gtr:outcomeId>06FFB776B9D</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G117/515</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>